Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma [clinicaltrials:NCT00003283]
Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma [clinicaltrials:NCT00003283]
Bio2RDF identifier
NCT00003283
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00003283
identifiers.org URI
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Drugs used i ...... astatic or recurrent thymoma.
brief title [clinicaltrials_vocabulary:brief-title]
Octreotide With or Without Pre ...... etastatic or Recurrent Thymoma
collaborator [clinicaltrials_vocabulary:collaborator]
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES: I. Determin ...... approximately 2
years.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-01T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
invasive thymoma and thymic carcinoma
recurrent thymoma and thymic carcinoma
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2010-01-26T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00003283
official title [clinicaltrials_vocabulary:official-title]
Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma
org study id [clinicaltrials_vocabulary:org-study-id]
CDR0000066197
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2003-09-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1998-07-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2010-01-01T00:00:00Z
identifier
clinicaltrials:NCT00003283
title
Octreotide With or Without Pre ...... etastatic or Recurrent Thymoma
@en
type
label
Octreotide With or Without Pre ...... a [clinicaltrials:NCT00003283]
@en